Can I switch from pramipexole 1 mg to ropinirole (Requip) 1 mg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Switching from Pramipexole to Ropinirole: Not Recommended

I strongly advise against switching from pramipexole 1 mg to ropinirole (Requip) 1 mg, as both medications carry similar risks of serious long-term complications, and a simple 1:1 dose conversion is pharmacologically incorrect and potentially harmful. 1, 2

Why This Switch Is Problematic

Both Drugs Are No Longer First-Line Therapy

The most recent 2025 American Academy of Sleep Medicine guidelines and 2026 Mayo Clinic algorithm conditionally recommend against the standard use of both pramipexole and ropinirole due to their high risk of augmentation (paradoxical worsening of symptoms) occurring in 42-70% of patients over 8-10 years 1, 2. Both medications share the same fundamental problems:

  • Augmentation risk: 5-7% per year with long-term use
  • Impulse control disorders: 6-17% of patients develop compulsive gambling, shopping, or hypersexual behaviors 2
  • Similar adverse effect profiles: nausea, orthostatic hypotension, somnolence, hallucinations 3

The Dose Conversion Is Wrong

A 1:1 conversion from pramipexole to ropinirole is pharmacologically incorrect. The evidence shows:

  • The appropriate conversion ratio is 1 mg pramipexole to 4 mg ropinirole (1:4 ratio) 4
  • Your proposed 1 mg ropinirole dose would represent a massive underdosing (approximately 75% reduction in dopaminergic effect)
  • This would likely cause severe symptom breakthrough and potential withdrawal symptoms

Specific Risks of This Switch

If you're considering this switch due to side effects or lack of efficacy:

  1. If experiencing augmentation on pramipexole: Switching to ropinirole will not solve the problem—both drugs cause augmentation at similar rates 1, 2

  2. If experiencing impulse control disorders: Recent 2024 data shows pramipexole may carry inherently higher ICD risk regardless of dose, while ropinirole's ICD risk is more dose-dependent 5. However, both remain problematic.

  3. Withdrawal risk: Abruptly stopping pramipexole can cause severe withdrawal symptoms including fever, confusion, severe muscle stiffness, depression, and anxiety 3

What You Should Do Instead

If You Must Switch Between Dopamine Agonists

Use the correct 1:4 conversion ratio (1 mg pramipexole = 4 mg ropinirole) and perform an overnight switch, which has been shown to be well-tolerated 4. However, this still doesn't address the fundamental problem that both drugs carry similar long-term risks.

Better Alternatives to Consider

Based on current 2025 guidelines, consider transitioning away from dopamine agonists entirely to 1:

  1. Iron supplementation (if ferritin appropriate): Ferrous sulfate or IV iron formulations (conditional to strong recommendations)
  2. Alpha-2-delta ligands: Gabapentin or pregabalin (preferred for long-term management)
  3. Opioids: Extended-release oxycodone (conditional recommendation, moderate certainty)
  4. Dipyridamole (conditional recommendation)

Critical Warning Signs to Monitor

If you proceed with any dopamine agonist, watch for augmentation symptoms 2:

  • Symptoms appearing earlier in the day than when first started
  • Need for higher doses to control symptoms
  • Increased intensity of symptoms
  • Symptoms spreading to arms or other body parts

Under no circumstances should you increase the dopamine agonist dose if these symptoms occur—this worsens augmentation 2.

Bottom Line

Do not perform a 1:1 switch from pramipexole 1 mg to ropinirole 1 mg. If switching between these agents is absolutely necessary, use the 1:4 conversion ratio (requiring 4 mg ropinirole). However, the better approach is to work with your healthcare provider to transition to alternative therapies that don't carry the same augmentation and impulse control disorder risks that plague both pramipexole and ropinirole.

References

Guideline

treatment of restless legs syndrome and periodic limb movement disorder: an american academy of sleep medicine clinical practice guideline.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2025

Research

An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.